Compare Rocket Lab USA Inc (RKLB) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rocket Lab USA Inc vs GeneDx Holdings Corp — how do they compare? Rocket Lab USA Inc trades at $68.3 (market cap $43.74B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Rocket Lab USA Inc is far larger — about 21.7× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is more actively traded (734,640 versus 22,892,581). Which is the better fit depends on your goals — on Pluang, investors hold Rocket Lab USA Inc for 29 Days and GeneDx Holdings Corp for 19 Days on average.
| RKLB | WGS | |
|---|---|---|
Market Cap | $43.74B | $2.02B |
Volume | 22,892,581 | 734,640 |
Sector | Industrials | Health |
52-Week High | $150.23 | $167.51 |
52-Week Low | $39.48 | $34.51 |
Typical Hold Time | 29 Days | 19 Days |
Enterprise Value | $41.57B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rocket Lab (RKLB) trades at $68.35, down 4.96% in the last session, reflecting a bearish technical trend. The company's fundamentals show strong revenue growth, with 2026 revenue projected at $769 million, but it remains unprofitable with a net loss of -$165 million. Recent positive news includes securing its largest-ever commercial Electron launch deal with Synspective, boosting its backlog to over 100 missions. Analyst sentiment is predominantly bullish, with a consensus price target of $107.00.
The outlook for RKLB hinges on execution of its growing launch backlog and path to profitability. Investment opportunity lies in its leading position in small satellite launch services and expanding spacecraft business. Key risks include intense competition from SpaceX, high cash burn, and reliance on future Neutron rocket success. The stock offers high growth potential but carries significant execution and valuation risks.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
